CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
The firm plans to use the funding to expand commercial sales efforts, advance CDx partnerships, build its regulatory infrastructure, and explore new R&D avenues.
The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.
The firm said the one-for-five reverse split will help address a looming delisting from the Nasdaq Capital Market by boosting the bid price per share above $1.00.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
NEW YORK (GenomeWeb News) – The University Medical Center at Johannes Gutenberg University Mainz in Germany (JGU) announced today separate deals to build out its capabilities in neuroscience research.
NEW YORK (GenomeWeb News) – Seahorse Biosciences said recently that it has licensed a patent from the Pioneer Valley Life Sciences Institute covering a method of analyzing the inner mechanics of a cell and how it makes and uses energy.
An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.
In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.
